Connection
Eric Wu to Protein-Tyrosine Kinases
This is a "connection" page, showing publications Eric Wu has written about Protein-Tyrosine Kinases.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.199 |
|
|
|
-
Signorovitch J, Ayyagari R, Reichmann WM, Wu EQ, Chen L. Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis. Cancer Treat Rev. 2014 Mar; 40(2):285-92.
Score: 0.081
-
Guérin A, Wu EQ, Bollu VK, Williams D, Guo A, de Leon DP, Quintas-Cardama A. The economic burden of pleural effusions in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Med Econ. 2013; 16(1):125-33.
Score: 0.074
-
Signorovitch JE, Betts KA, Reichmann WM, Thomason D, Galebach P, Wu EQ, Chen L, DeAngelo DJ. One-year and long-term molecular response to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison. Curr Med Res Opin. 2015 Feb; 31(2):315-22.
Score: 0.022
-
Guérin A, Chen L, Dea K, Wu EQ, Goldberg SL. Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase. Curr Med Res Opin. 2014 Jul; 30(7):1345-52.
Score: 0.021